1. Home
  2. KPTI vs IMUX Comparison

KPTI vs IMUX Comparison

Compare KPTI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • IMUX
  • Stock Information
  • Founded
  • KPTI 2008
  • IMUX 2016
  • Country
  • KPTI United States
  • IMUX United States
  • Employees
  • KPTI N/A
  • IMUX N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • IMUX Biotechnology: Pharmaceutical Preparations
  • Sector
  • KPTI Health Care
  • IMUX Health Care
  • Exchange
  • KPTI Nasdaq
  • IMUX Nasdaq
  • Market Cap
  • KPTI 81.1M
  • IMUX 86.3M
  • IPO Year
  • KPTI 2013
  • IMUX N/A
  • Fundamental
  • Price
  • KPTI $0.59
  • IMUX $0.94
  • Analyst Decision
  • KPTI Strong Buy
  • IMUX Strong Buy
  • Analyst Count
  • KPTI 4
  • IMUX 6
  • Target Price
  • KPTI $5.00
  • IMUX $12.67
  • AVG Volume (30 Days)
  • KPTI 698.5K
  • IMUX 946.7K
  • Earning Date
  • KPTI 02-19-2025
  • IMUX 02-20-2025
  • Dividend Yield
  • KPTI N/A
  • IMUX N/A
  • EPS Growth
  • KPTI N/A
  • IMUX N/A
  • EPS
  • KPTI N/A
  • IMUX N/A
  • Revenue
  • KPTI $148,442,000.00
  • IMUX N/A
  • Revenue This Year
  • KPTI $4.47
  • IMUX N/A
  • Revenue Next Year
  • KPTI $7.35
  • IMUX N/A
  • P/E Ratio
  • KPTI N/A
  • IMUX N/A
  • Revenue Growth
  • KPTI 1.77
  • IMUX N/A
  • 52 Week Low
  • KPTI $0.58
  • IMUX $0.92
  • 52 Week High
  • KPTI $1.70
  • IMUX $2.11
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 37.30
  • IMUX 38.85
  • Support Level
  • KPTI $0.60
  • IMUX $0.94
  • Resistance Level
  • KPTI $0.67
  • IMUX $1.02
  • Average True Range (ATR)
  • KPTI 0.05
  • IMUX 0.06
  • MACD
  • KPTI -0.00
  • IMUX 0.00
  • Stochastic Oscillator
  • KPTI 4.16
  • IMUX 13.58

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: